Innovative British Medical Device Company providing options for all of your EVAR and TEVAR needs http://linkedin.com/company/lombar…
Location: United Kingdom, England, South Oxfordshire
Total raised: $20M
Founded date: 1994
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.06.2010 | Series A | $20M | - |
Mentions in press and media 13
| Date | Title | Description |
| 23.08.2016 | Lombard Medical goes for Americexit and possible sale | Lombard Medical laid the blame for its Americexit on an FDA decision that would require it to perform a 50-patient IDE (investigational device exemption) trial for the U.S. approval of its next-generation IntelliFlex delivery system. “Unfor... |
| 29.04.2015 | Lombard Medical takes out $26m loan for Aorfix stent graft | Lombard Medical Technologies (NSDQ:EVAR) yesterday said it took out a $26 million term loan from Oxford Finance it plans to use in funding the global rollout of its Aorfix stent graft for treating abdominal aortic aneurysms. Irvine, Calif.-... |
| 31.03.2014 | Lombard Medical sets range for $55m – $65M IPO | Lombard Medical Technologies (LON:LMT) today set the range for its forthcoming U.S. initial public offering, saying it plans to price its shares between $15 apiece and $18. That would mean the British medical device company, which makes ste... |
| 11.03.2014 | Lombard Medical seeks up to $80M in U.S. IPO | Lombard Medical Technologies (LON:LMT) said yesterday that it could raise up to $80 million in its debut on the U.S. stock market. The British medical device company, which makes stent grafts to repair abdominal aortic aneurysms, said it pl... |
| 08.01.2014 | London’s Lombard Medical seeks U.S. IPO | U.K. medical device maker Lombard Medical Technologies (LON:LMT) today announced plans to launch a U.S. initial public offering, swapping its ordinary shares from their current listing on the London Stock Exchange. Lombard, which makes sten... |
| 09.08.2013 | Ex-Accuray CEO Thomson is new chief at AliveCor | Personnel Moves | Former Accuray (NSDQ:ARAY) CEO Euan Thomson was named interim CEO at AliveCor following the departure of Daniel Sullivan after just 4 months on the job. Thomson, a partner at Khosla Ventures, an investor in AliveCor’s Series B funding round... |
| 21.06.2013 | Lombard Medical lands Aorflex FDA approval, $32M | Fresh off of a $32 million funding round, Lombard Medical Technologies (LON:LMT) said it won pre-market approval from the FDA for the Aorflex delivery system used with its Aorfix stent graft for treating abdominal aortic aneurysms. The Brit... |
| 15.02.2013 | FDA approves Lombard Med. Tech.’s Aorfix stent graft for treating highest neck angulation | British medical device maker Lombard Medical Technologies (LON:LMT) won premarket approval from the FDA to market its Aorfix flexible stent graft in the U.S. The FDA win gives Lombard permission to market the Aorfix device in treatment of c... |
| 20.12.2012 | Negative rating slashes 10% from Intuitive Surgical | Wall Street Beat | A research report blasting Intuitive Surgical (NSDQ:ISRG) spooked investors on Wall Street yesterday and today, prompting a selloff that’s shaved some 11% from the medical device company’s share price. Citron Research, citing several factor... |
| 19.06.2012 | Stentys’ Apposition stent goes head-to-head against Medtronic’s Resolute | Studies Roundup | Stentys SA (EPA:STNT) is looking to prove its next-generation Apposition IV stent in a head-to-head study against Medtronic’s (NYSE:MDT) Resolute. Stentys calls its suite of Apposition stents the "world’s 1st and only self-apposing ste... |
Show more